Midodrine Effect on the Mortality Rates in Septic Shock Patients

Noha Mansour100 enrolled

Overview

Assessing the safety and efficacy of the adjunctive use of midodrine as a vasopressor in septic shock patients by measuring the difference in the mortality rates between control and intervention groups.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

100

Conditions

Septic Shock

Interventions

Midodrine Oral TabletDRUG

Patients will receive standard treatment in accordance to surviving sepsis campaign guidelines plus oral midodrine 10 mg/ 8 hours till the end of treatment (subject remaining vasopressor-free for 24 consecutive hours) or death.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult aged 18 years or older diagnosed with septic shock. * Hypotensive and require IV vasopressor for more than 24 hours. Exclusion Criteria: * Hypovolemic shock. * Severe organic heart disease (ejection fraction \<30 percent). * Bradycardia (HR\<50 b/m). * Chronic kidney disease (serum creatinine \>2mg/dl). * Thyrotoxicosis. * Pheochromocytoma. * Known allergy to midodrine. * Unable to administer an oral medication.

Locations (1)

Mansoura University

Al Mansurah, Egypt

Outcomes

Primary Outcomes

Mortality rates

The primary outcome is measuring the difference in ICU mortality rates between control and intervention group.

Time frame: Time Frame: Starting from date of randomization till shock reversal or date of death from any cause, whichever came first,assessed up to 30 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.